Xinchun Yang

Xinchun Yang

Auto-generated profile, based on publicly available information

Xinchun Yang

Heart Center and Beijing Key Laboratory of Hypertension Beijing Chaoyang Hospital Affiliated to Capital Medical University Beijing China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JWJuan Wang
Juan Wang
LWLiqun Wei
Liqun Wei
XYXinchun Yang
Xinchun Yang
JZJiu-Chang Zhong
Jiu-Chang Zhong

1 January 2018
Verified
Journal Article
Open access
JWJuan Wang
Juan Wang
DZDa-Peng Zhang
Da-Peng Zhang
HLHong–Bin Liu
Hong–Bin Liu
JZJiu-Chang Zhong
Jiu-Chang Zhong
XYXin–Chun Yang
Xin–Chun Yang
Hypertension has been found to be increased a risk of stroke in atrial fibrillation (AF). Both the European and U.S. guidelines advocate the use of the CHA2DS2-VASc (congestive heart failure, hypertension, age > 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category) scheme for risk stratification. Although vitamin K antagonists is more effective than acetylsalicylic acid at preventing ischaemic stroke, its benefit is offs by an increased haemorrhage risk. The risk of ischemic stroke in patients with AF and a CHA2DS2-VASc score of 1 are considered to be low risk and may be not expected to benefit from anticoagulation therapy. Hypertension carries an increased risk of ischemic stroke, however, it is also a clear risk factor for hemorrhage in AF. Therefore, the optimal antithrombotic management is highlighted in patients with AF with only one risk factor especially hypertension.